Cushing's Syndrome - Pipeline Review, Q2 2011
Global Markets Direct’s, 'Cushing's Syndrome - Pipeline Review, Q2 2011', provides an overview of the Cushing's Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Cushing's Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cushing's Syndrome. 'Cushing's Syndrome - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Cushing's Syndrome.
- A review of the Cushing's Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cushing's Syndrome pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Cushing's Syndrome.
- Identify emerging players with potentially strong product
Cushing's Syndrome – Pipeline Review, Q2 2011 Cushing's Syndrome - Pipeline Review, Q2 2011 Reference Code: GMDHC1008IDB Publication Date: April 2011 Cushing's Syndrome – Pipeline Review, Q2 2011 GMDHC1008IDB / Pub April 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Cushing's Syndrome – Pipeline Review, Q2 2011 Ta b le o f Co n te n ts Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Cushing's Syndrome Overview 6 Therapeutics Development 7 An Overview of Pipeline Products for Cushing's Syndrome 7 Cushing's Syndrome Therapeutics under Development by Companies 9 Cushing's Syndrome Therapeutics under Investigation by Universities/Institutes 10 Late Stage Products 12 Comparative Analysis 12 Mid Clinical Stage Products 13 Comparative Analysis 13 Early Clinical Stage Products 14 Comparative Analysis 14 Pre-Clinical Stage Products 15 Comparative Analysis 15 Cushing's Syndrome Therapeutics - Products under Development by Companies 16 Cushing's Syndrome Therapeutics - Products under Investigation by Universities/Institutes 17 Companies Involved in Cushing's Syndrome Therapeutics Development 18 Ipsen S.A. 18 Novartis AG 18 Corcept Therapeutics Incorporated 19 Samaritan Pharmaceuticals, Inc. 19 HRA Pharma, SA 20 Cushing's Syndrome - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 Pasireotide - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Mifedren - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Corlux - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 SP-6300 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Cushing's Syndrome – Pipeline Review, Q2 2011 GMDHC1008IDB / Pub April 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2) Cushing's Syndrome – Pipeline Review, Q2 2011 Bexarotene for Cushing's Disease - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Mifepristone - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Cabergoline - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Rosiglitazone Maleate - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Cabergoline - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Mifepristone - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Inhibitors Of ACTH Receptor - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Cushing's Syndrome Therapeutics – Drug Profile Updates 39 Cushing's Syndrome - Featured News 40 Mar 31, 2011: Corcept To Submit NDA For Use Of CORLU
Pages to are hidden for
"Cushing's Syndrome - Pipeline Review, Q2 2011"Please download to view full document